| Literature DB >> 35493173 |
Letícia Cristina Assis1, Alexandre Alves de Castro1, João Paulo Almirão de Jesus2, Elaine Fontes Ferreira da Cunha1, Eugenie Nepovimova3, Ondrej Krejcar4, Kamil Kuca3, Teodorico Castro Ramalho1,3, Felipe de Almeida La Porta2.
Abstract
In this study, we systematically investigated the electronic structure, spectroscopic (nuclear magnetic resonance, infrared, Raman, electron ionization mass spectrometry, UV-Vis, circular dichroism, and emission) properties, and tautomerism of halogenated favipiravir compounds (fluorine, chlorine, and bromine) from a computational perspective. Additionally, the effects of hydration on the proton transfer mechanism of the tautomeric forms of the halogenated favipiravir compounds are discussed. Our results suggest that spectroscopic properties allow for the elucidation of such tautomeric forms. As is well-known, the favipiravir compound has excellent antiviral properties and hence was recently tested for the treatment of new coronavirus (SARS-CoV-2). Through in silico modeling, in the current study, we evaluate the role of such tautomeric forms in order to consider the effect of drug-metabolism in the inhibition process of the main protease (Mpro) and RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 virus. According to the molecular docking, all halogenated compounds presented a better interaction energy than the co-crystallized active ligand (-3.5 kcal mol-1) in the viral RdRp, in both wild-type (-6.3 to -6.5 kcal mol-1) and variant (-5.4 to -5.6 kcal mol-1) models. The variant analyzed for RdRp (Y176C) decreases the affinity of the keto form of the compounds in the active site, and prevented the ligands from interacting with RNA. These findings clearly indicated that all these compounds are promising as drug candidates for this molecular target. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35493173 PMCID: PMC9042810 DOI: 10.1039/d1ra06309j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Chemical structure and tautomeric form of favipiravir.
Fig. 2Optimized structures and ESP maps (with surface isovalue of 0.0004) for the halogenated favipiravir tautomeric forms: (a) 1-F; (b) 1-Cl; (c) 1-Br; (d) 2-F; (e) 2-Cl and (f) 2-Br.
Fig. 3Computed (a) IR and (b) Raman spectra of the derivatives.
Fig. 4Computed (a and b) UV-Vis and emission, (c and d) ECD spectra and (e) MOs shapes (with a surface isovalue of 0.03) of both (a) 1 and (b) 2 derivative tautomer forms.
Analysis of UV-Vis and emission spectra of both 1 and 2 derivative tautomer forms
| Molecule | Excitonic transition | Absorbance wavelength (nm) | Emission | Emission wavelength (nm) | Stokes shift (nm) |
|---|---|---|---|---|---|
| 1-F | HOMO → LUMO | 350 | LUMO → HOMO | 454 | 104 |
| HOMO−4 → LUMO | 241 | ||||
| 1-Cl | HOMO → LUMO | 350 | LUMO → HOMO | 437 | 87 |
| HOMO−4 → LUMO | 245 | ||||
| 1-Br | HOMO → LUMO | 361 | LUMO → HOMO | 437 | 76 |
| 2-F | HOMO−1 → LUMO | 291 | LUMO → HOMO | 312 | 21 |
| 2-Cl | HOMO−1 → LUMO | 296 | LUMO → HOMO | 319 | 23 |
| 2-Br | HOMO−2 → LUMO | 304 | LUMO → HOMO | 336 | 32 |
Electronic properties of the derivatives in gas phase and solution
| Molecule | HOMO–LUMO (eV) | Hardness (eV) | Softness (eV) | Mulliken electronegativity (eV) | Electrophilicity (eV) |
|---|---|---|---|---|---|
|
| |||||
| 1-F | 3.88 | 1.94 | 0.51 | −5.02 | 50.40 |
| 1-Cl | 3.91 | 1.95 | 0.51 | −4.98 | 49.70 |
| 1-Br | 3.83 | 1.91 | 0.52 | −4.98 | 49.70 |
| 2-F | 4.62 | 2.31 | 0.43 | −5.02 | 50.40 |
| 2-Cl | 4.64 | 2.32 | 0.43 | −5.00 | 50.00 |
| 2-Br | 4.58 | 2.29 | 0.44 | −4.96 | 49.20 |
|
| |||||
| 1-F | 3.95 | 1.97 | 0.51 | −4.87 | 47.53 |
| 1-Cl | 3.98 | 1.99 | 0.50 | −4.84 | 46.85 |
| 1-Br | 3.89 | 1.94 | 0.51 | −4.83 | 46.75 |
| 2-F | 4.70 | 2.35 | 0.42 | −4.96 | 49.2 |
| 2-Cl | 4.67 | 2.33 | 0.43 | −4.91 | 48.31 |
| 2-Br | 4.59 | 2.29 | 0.44 | −4.87 | 47.53 |
Fig. 5EI-MS diagrams, trajectories and intermediaries of all studied derivatives. (A) 1-F, (B) 1-Cl, (C) 1-Br, (D) 2-F, (E) 2-Cl and (F) 2-Br structures.
NMR shielding on nuclei of intermediaries in gas phase and in solvent water (PCM)
| Molecule | Nuclei | Shielding in gas (ppm) | Shielding in water (ppm) | Δ |
|---|---|---|---|---|
|
| 12-O | −66.26 | −7.82 | −58.44 |
| 7-N | −44.26 | −46.37 | 2.11 | |
| 10-O | −31.38 | 21.56 | −52.94 | |
| 9-H | 23.90 | 22.87 | 1.03 | |
| 5-H | 24.68 | 24.05 | 0.63 | |
| 14-H | 24.93 | 24.46 | 0.47 | |
| 15-H | 27.08 | 26.61 | 0.47 | |
| 11-C | 36.18 | 32.97 | 3.21 | |
| 4-C | 48.12 | 44.99 | 3.13 | |
| 2-C | 48.29 | 48.13 | 0.16 | |
| 3-C | 51.00 | 53.71 | −2.71 | |
| 1-C | 79.01 | 73.18 | 5.83 | |
| 8-N | 85.17 | 74.69 | 10.48 | |
| 13-N | 171.85 | 165.03 | 6.82 | |
| 6-F | 301.55 | 303.73 | −2.18 | |
|
| 6-N | −67.44 | −71.64 | 4.20 |
| 11-O | −64.36 | −7.16 | −57.20 | |
| 9-O | −35.90 | 16.12 | −52.02 | |
| 8-H | 23.71 | 22.74 | 0.97 | |
| 5-H | 24.62 | 24.04 | 0.58 | |
| 13-H | 24.93 | 24.46 | 0.47 | |
| 14-H | 27.10 | 26.64 | 0.46 | |
| 10-C | 36.37 | 33.16 | 3.21 | |
| 4-C | 48.75 | 45.66 | 3.09 | |
| 3-C | 48.76 | 51.05 | −2.29 | |
| 2-C | 63.68 | 63.07 | 0.61 | |
| 1-C | 66.99 | 61.93 | 5.06 | |
| 7-N | 80.44 | 71.40 | 9.04 | |
| 12-N | 172.46 | 165.63 | 6.83 | |
| 15-Cl | 708.05 | 709.13 | −1.08 | |
|
| 6-N | −73.15 | −78.22 | 5.07 |
| 11-O | −66.76 | −4.09 | −62.67 | |
| 9-O | −37.07 | 15.66 | −52.73 | |
| 8-H | 23.61 | 22.67 | 0.94 | |
| 5-H | 24.46 | 23.91 | 0.55 | |
| 13-H | 24.60 | 24.13 | 0.47 | |
| 14-H | 27.06 | 26.61 | 0.45 | |
| 10-C | 37.34 | 34.27 | 3.07 | |
| 4-C | 49.03 | 45.73 | 3.30 | |
| 3-C | 50.48 | 52.34 | −1.86 | |
| 1-C | 63.45 | 58.69 | 4.76 | |
| 2-C | 65.41 | 64.33 | 1.08 | |
| 7-N | 76.38 | 67.91 | 8.47 | |
| 12-N | 173.11 | 166.53 | 6.58 | |
| 15-Br | 2213.46 | 2212.032 | −1998.57 | |
|
| 10-O | −54.27 | −4.43 | −49.84 |
| 8-N | −47.51 | −46.56 | −0.95 | |
| 7-N | −29.68 | −28.50 | −1.18 | |
| 5-H | 23.62 | 23.33 | 0.29 | |
| 12-H | 24.39 | 23.98 | 0.41 | |
| 15-H | 25.52 | 25.02 | 0.50 | |
| 13-H | 26.83 | 26.35 | 0.48 | |
| 9-C | 36.61 | 33.93 | 2.68 | |
| 4-C | 39.07 | 38.86 | 0.21 | |
| 2-C | 40.63 | 40.58 | 0.05 | |
| 1-C | 62.54 | 59.77 | 2.77 | |
| 3-C | 67.54 | 68.03 | −0.49 | |
| 11-N | 170.19 | 163.66 | 6.53 | |
| 14-O | 190.07 | 196.21 | −6.14 | |
| 6-F | 282.12 | 285.63 | −3.51 | |
|
| 6-N | −61.30 | −60.84 | −0.46 |
| 9-O | −52.74 | −3.71 | −49.03 | |
| 7-N | −41.79 | −40.70 | −1.09 | |
| 5-H | 23.57 | 23.32 | 0.25 | |
| 11-H | 24.31 | 23.91 | 0.40 | |
| 15-H | 25.53 | 25.02 | 0.51 | |
| 12-H | 26.84 | 26.36 | 0.48 | |
| 8-C | 36.27 | 33.62 | 2.65 | |
| 4-C | 38.52 | 38.23 | 0.29 | |
| 2-C | 49.23 | 49.08 | 0.15 | |
| 1-C | 51.29 | 49.11 | 2.18 | |
| 3-C | 65.03 | 65.38 | −0.35 | |
| 10-N | 169.91 | 163.55 | 6.36 | |
| 14-O | 189.35 | 195.18 | −5.83 | |
| 13-Cl | 686.88 | 689.91 | −3.03 | |
|
| 6-N | −67.78 | −67.52 | −0.26 |
| 9-O | −52.47 | −3.52 | −48.95 | |
| 7-N | −41.34 | −40.11 | −1.23 | |
| 5-H | 23.43 | 23.20 | 0.23 | |
| 11-H | 24.30 | 23.89 | 0.41 | |
| 15-H | 25.56 | 25.04 | 0.52 | |
| 12-H | 26.83 | 26.36 | 0.47 | |
| 8-C | 36.39 | 33.75 | 2.64 | |
| 4-C | 37.97 | 37.70 | 0.27 | |
| 2-C | 48.40 | 48.12 | 0.28 | |
| 1-C | 48.60 | 46.62 | 1.98 | |
| 3-C | 63.70 | 64.03 | −0.33 | |
| 10-N | 170.51 | 164.07 | 6.44 | |
| 14-O | 189.30 | 195.14 | −5.84 | |
| 13-Br | 2182.22 | 2185.65 | −3.43 |
Fig. 6Re-docking overlaps and representation of the interactions performed by co-crystallized 6-(ethylamino)pyridine-3-carbonitrile for SARS-CoV-2 Mpro and cytidine-5′-triphosphate for SARS-CoV-2 RdRp sites. Interactions: green = Hydrogen bond, pink = hydrophobic and orange = coulombians.
Intermolecular interaction energies obtained through Vina
| Compounds | Intermolecular interactions and energy (kcal mol−1) | |||||
|---|---|---|---|---|---|---|
| RdRp ( | H-Bond | RdRp (Y176C) | H-Bond | Mpro ( | H-Bond | |
|
| −6.5 | Ser300, Asp247, Asp343, Tpr246, Asn309, G8 | −5.6 | Asn309, Trp246 | −4.4 | His41 |
|
| −6.5 | Ser300, Asp247, Asp343, Asn309, G8 | −5.6 | Trp246, Asn309 | −4.4 | Gln189, His41 |
|
| −6.4 | Arg182, Asn309, Asp343, Trp246, G8 | −5.5 | Trp246, Asn309 | −4.8 | His164, Arg188 |
|
| −6.3 | Arg182, Asp343, G8 | −5.4 | Arg182, Asp247, Gln66, Ser246, | −4.6 | Arg188, Gln189, His41, His164 |
|
| −6.3 | Arg182, Asn309, Asp343, G8 | −5.5 | Tyr243, Asp343, Arg182, Asp247 | −4.6 | Gln189, His41 |
|
| −6.3 | Arg182, Asp343, Asn309, G8, Trp246 | −5.4 | Arg182, Asp242, Tyr243, Asp343, Asp247 | −4.7 | Gln189, His164, His41 |
Fig. 7Representation of the interactions performed by favipiravir and its derivatives in the SARS-CoV-2 RNA polymerase site.
Fig. 8Representation of the interactions performed by favipiravir and its derivatives in the Mpro active site.
ADMET profile of selected favipiravir derivativesa (ref. [72])
| Comp. | MW | log | DH/AH | log | Intestinal absorption (%) | CNS | Tox. (LD50) |
|---|---|---|---|---|---|---|---|
| 1-F | 157.10 | -0.99 | 2/3 | −1.45 | 86.80 | −3.06 | 1.92 |
| 1-Cl | 173.56 | −0.48 | 2/3 | −1.94 | 87.00 | −3.07 | 2.12 |
| 1-Br | 218.01 | −0.37 | 2/3 | −2.03 | 86.95 | −3.06 | 2.13 |
| 2-F | 157.10 | −0.58 | 2/4 | −1.88 | 86.04 | −3.12 | 1.52 |
| 2-Cl | 173.56 | −0.06 | 2/4 | −2.29 | 86.59 | −3.11 | 1.8 |
| 2-Br | 218.01 | 0.04 | 2/4 | −2.36 | 86.53 | −3.11 | 1.81 |
Comp = compounds favipiravir derivatives. ADME parameters: MW = molecular weight, DH = number of H bonds donors, AB = number of H bonds acceptors, log P = partition coefficient, log S = predicted aqueous solubility, CNS = predicted central nervous system, Tox = oral rat acute toxicity (mol kg−1).
| Gas phase | ||||
|---|---|---|---|---|
| Cl |
|
|
|
|
| Energy = −967.82 a.u. | Energy = −1044.31 a.u. | Energy = −1120.76 a.u. | Energy = −1197.21 a.u. | |
| NIMAG = −1878.14 cm−1 | NIMAG = −1453.72 cm−1 | NIMAG = −1216.46 cm−1 | NIMAG = −357.30 cm−1 | |
| Br |
|
|
|
|
| Energy = −3079.35 a.u. | Energy = −3155.84 a.u. | Energy = −3232.29 a.u. | Energy = −3308.74 a.u. | |
| NIMAG = −1877.99 cm−1 | NIMAG = −1450.93 cm−1 | NIMAG = −1214.20 cm−1 | NIMAG = −355.42 cm−1 | |
| F |
|
|
|
|
| Energy = −607.47 a.u. | Energy = −683.96 a.u. | Energy = −760.41 a.u. | Energy = −836.86 a.u. | |
| NIMAG = −1915.94 cm−1 | NIMAG = −1003.52 cm−1 | NIMAG = −1249.76 cm−1 | NIMAG = −417.01 cm−1 | |
| Implicit solvent (water) | ||||
|---|---|---|---|---|
| Cl |
|
|
|
|
| Energy = −967.84 a.u. | Energy = −1044.33 a.u. | Energy = −1120.79 a.u. | Energy = −1197.24 a.u. | |
| NIMAG = −1913.03 cm−1 | NIMAG = −941.77 cm−1 | NIMAG = −738.36 cm−1 | NIMAG = −101.61 cm−1 | |
| Br |
|
|
|
|
| Energy = −3079.37 a.u. | Energy = −3155.86 a.u. | Energy = −3232.32 a.u. | Energy = −3308.77 a.u. | |
| NIMAG = −1913.72 cm−1 | NIMAG = −930.60 cm−1 | NIMAG = −744.43 cm−1 | NIMAG = −133.15 cm−1 | |
| F |
|
|
|
|
| Energy = −607.48 a.u. | Energy = −683.98 a.u. | Energy = −760.44 a.u. | Energy = −836.89 a.u. | |
| NIMAG = −1915.94 cm−1 | NIMAG = −1003.52 cm−1 | NIMAG = −753.77 cm−1 | NIMAG = −139.32 cm−1 | |